TBPH Theravance Biopharma, Inc. Stock Quote

TBPH [NASD]

Healthcare | Biotechnology | Cayman Islands

Index	-	P/E	-	EPS (ttm)	-4.73	Insider Own	6.40%	Shs Outstand	63.30M	Perf Week	-7.93%
Market Cap	1.11B	Forward P/E	-	EPS next Y	-2.85	Insider Trans	-0.29%	Shs Float	51.21M	Perf Month	-6.53%
Income	-285.20M	PEG	-	EPS next Q	-1.02	Inst Own	87.10%	Short Float	6.59%	Perf Quarter	6.65%
Sales	82.60M	P/S	13.41	EPS this Y	-6.50%	Inst Trans	2.87%	Short Ratio	10.08	Perf Half Y	-3.51%
Book/sh	-4.13	P/B	-	EPS next Y	36.80%	ROA	-54.60%	Target Price	31.22	Perf Year	-27.18%
Cash/sh	5.60	P/C	3.09	EPS next 5Y	6.70%	ROE	134.90%	52W Range	14.48 - 31.35	Perf YTD	-2.59%
Dividend	-	P/FCF	-	EPS past 5Y	10.60%	ROI	-106.70%	52W High	-44.78%	Beta	0.93
Dividend %	-	Quick Ratio	4.30	Sales past 5Y	44.40%	Gross Margin	-	52W Low	19.54%	ATR	1.03
Employees	316	Current Ratio	4.30	Sales Q/Q	47.60%	Oper. Margin	-	RSI (14)	34.01	Volatility	6.41% 5.57%
Optionable	Yes	Debt/Eq	-	EPS Q/Q	-11.20%	Profit Margin	-	Rel Volume	1.15	Prev Close	17.49
Shortable	Yes	LT Debt/Eq	-	Earnings	Feb 23 AMC	Payout	-	Avg Volume	334.87K	Price	17.31
Recom	2.20	SMA20	-9.60%	SMA50	-6.70%	SMA200	-11.54%	Volume	385,245	Change	-1.03%

Oct-14-20

Upgrade

Morgan Stanley

Equal-Weight → Overweight

$32

Jul-07-20

Initiated

JP Morgan

Overweight

$29

Jun-15-20

Initiated

Morgan Stanley

Equal-Weight

$30

May-13-20

Initiated

Cowen

Outperform

$42

Jan-08-20

Reiterated

H.C. Wainwright

Buy

$25 → $30

Nov-06-19

Upgrade

Robert W. Baird

Underperform → Neutral

$22 → $18

Oct-29-19

Initiated

H.C. Wainwright

Buy

$25

Mar-29-18

Resumed

Piper Jaffray

Overweight

$45

Aug-17-17

Initiated

Evercore ISI

Outperform

$45

Jun-16-17

Initiated

Cantor Fitzgerald

Overweight

$55

May-11-17

Reiterated

Needham

Buy

$40 → $45

Dec-21-16

Initiated

Needham

Buy

$40

Nov-03-16

Initiated

Piper Jaffray

Overweight

Oct-12-16

Downgrade

Robert W. Baird

Neutral → Underperform

$19 → $24

Aug-03-16

Downgrade

BofA/Merrill

Neutral → Underperform

Jun-20-16

Reiterated

Leerink Partners

Outperform

$26 → $29

Jun-20-16

Initiated

Guggenheim

Buy

$30

May-12-16

Initiated

Leerink Partners

Outperform

$26

May-05-16

Downgrade

BofA/Merrill

Buy → Neutral

Feb-03-15

Upgrade

Robert W. Baird

Underperform → Neutral

$13 → $17

Feb-24-21 06:32AM	Theravance Biopharma Inc (TBPH) Q4 2020 Earnings Call Transcript Motley Fool
Feb-23-21 04:45PM	Theravance Biopharma: Q4 Earnings Insights Benzinga
03:15PM	Theravance Biopharma, Inc. to Host Earnings Call ACCESSWIRE
Feb-22-21 10:16AM	Theravance Biopharma Earnings Preview Benzinga
Feb-10-21 06:00AM	Theravance Biopharma to Participate in Upcoming Investor Conferences PR Newswire
Feb-09-21 06:00AM	Theravance Biopharma to Report Fourth Quarter and Full Year 2020 Financial Results on February 23, 2021 PR Newswire
Jan-14-21 12:00PM	2 Strong Buy Stocks Trading at Steep Discounts TipRanks
Jan-05-21 06:00AM	Theravance Biopharma To Present at the 39th Annual J.P. Morgan Healthcare Conference PR Newswire
Dec-19-20 01:06PM	Is TBPH A Good Stock To Buy According To Hedge Funds? Insider Monkey
Dec-05-20 11:32AM	Theravance Bio (TBPH) Down 12.5% Since Last Earnings Report: Can It Rebound? Zacks
Nov-17-20 06:00AM	Theravance Biopharma to Present at the 3rd Annual Evercore ISI HEALTHCONx Conference PR Newswire
Nov-09-20 12:17PM	Theravance (TBPH) Drops on Q3 Earnings Miss, Revenues In Line Zacks +6.40%
10:20AM	Analysts Have Lowered Expectations For Theravance Biopharma, Inc. (NASDAQ:TBPH) After Its Latest Results Simply Wall St.
Nov-07-20 01:31AM	Theravance Biopharma Inc (TBPH) Q3 2020 Earnings Call Transcript Motley Fool
Nov-05-20 07:05PM	Theravance Biopharma (TBPH) Reports Q3 Loss, Tops Revenue Estimates Zacks
03:30PM	Theravance Biopharma, Inc. to Host Earnings Call ACCESSWIRE
Oct-29-20 12:34PM	Theravance Biopharma (TBPH) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release Zacks
Oct-27-20 01:19PM	Would Shareholders Who Purchased Theravance Biopharma's (NASDAQ:TBPH) Stock Three Years Be Happy With The Share price Today? Simply Wall St.
Oct-22-20 06:00AM	Theravance Biopharma to Report Third Quarter 2020 Financial Results on November 5, 2020 PR Newswire +5.31%
Oct-19-20 10:39AM	Hedge Funds Have Never Been This Bullish On Theravance Biopharma Inc (TBPH) Insider Monkey
Sep-05-20 11:31AM	Why Is Theravance Bio (TBPH) Down 17.7% Since Last Earnings Report? Zacks
Sep-01-20 06:00AM	Theravance Biopharma to Present at Upcoming Investor Conferences PR Newswire
Aug-07-20 01:27PM	Theravance (TBPH) Earnings & Revenues Miss Estimates in Q2 Zacks -13.82%
Aug-06-20 06:35PM	Theravance Biopharma (TBPH) Reports Q2 Loss, Lags Revenue Estimates Zacks
04:34PM	Theravance Biopharma, Inc. Reports Second Quarter 2020 Financial Results and Provides Business Update PR Newswire
Jul-30-20 12:34PM	Theravance Biopharma (TBPH) Expected to Beat Earnings Estimates: Can the Stock Move Higher? Zacks
Jul-27-20 06:00AM	Theravance Biopharma to Report Second Quarter 2020 Financial Results on August 6, 2020 PR Newswire
Jul-22-20 12:32PM	Theravance Biopharma (TBPH) Expected to Beat Earnings Estimates: Can the Stock Move Higher? Zacks
Jul-02-20 06:00AM	Theravance Biopharma Appoints Deepika R. Pakianathan, Ph.D. to Board of Directors PR Newswire
Jun-29-20 03:50PM	Hedge Funds Have Never Been More Bullish On Theravance Biopharma Inc (TBPH) Insider Monkey
Jun-26-20 12:04PM	Theravance Doses First Patient in Phase II Coronavirus Study Zacks
Jun-25-20 08:26AM	The Daily Biotech Pulse: Merck's Wonder Cancer Drug Snags Another Approval, Decision Day For Zogenix, UniQure Out-Licenses Gene Therapy Benzinga
06:00AM	Theravance Biopharma Announces First Patient Dosed in Phase 2 Study of TD-0903 for the Treatment of Hospitalized Patients with Acute Lung Injury Caused by COVID-19 PR Newswire
Jun-17-20 09:38PM	GSK Finance (No.3) plc -- Moody's assigns A2 rating to GSK Finance (No.3) plc's proposed exchangeable notes Moody's -9.05%
Jun-15-20 09:57AM	Benzinga's Top Upgrades, Downgrades For June 15, 2020 Benzinga -6.61%
Jun-05-20 11:31AM	Theravance Bio (TBPH) Down 2.7% Since Last Earnings Report: Can It Rebound? Zacks
Jun-02-20 09:02PM	Edited Transcript of TBPH earnings conference call or presentation 6-May-20 9:00pm GMT Thomson Reuters StreetEvents
May-08-20 02:31PM	Theravance Biopharma Inc (TBPH) Q1 2020 Earnings Call Transcript Motley Fool
May-07-20 01:57PM	Theravance (TBPH) Q1 Earnings Miss, Revenues Beat Estimates Zacks
May-06-20 07:35PM	Theravance Biopharma (TBPH) Reports Q1 Loss, Tops Revenue Estimates Zacks
Apr-29-20 12:33PM	Will Theravance Biopharma (TBPH) Report Negative Earnings Next Week? What You Should Know Zacks
Apr-28-20 12:33PM	Will Theravance Biopharma (TBPH) Report Negative Q1 Earnings? What You Should Know Zacks
10:35AM	Here's What We Think About Theravance Biopharma, Inc.'s (NASDAQ:TBPH) CEO Pay Simply Wall St.
06:00AM	Theravance Biopharma to Report First Quarter 2020 Financial Results on May 6, 2020 PR Newswire
Apr-23-20 06:00AM	Theravance Biopharma Announces First Subject Dosed in Phase 1 Study of TD-0903, in Development for the Treatment of Hospitalized Patients with Acute Lung Injury Caused by COVID-19 PR Newswire
Apr-20-20 06:00AM	Theravance Biopharma Announces Peer-Reviewed Publication Highlighting TD-1473 Program in the Journal of Crohn's and Colitis PR Newswire
Apr-14-20 04:41PM	Seth Klarman Dials Down Akebia Therapeutics Stake GuruFocus.com
Apr-09-20 07:00AM	Theravance Biopharma Responds to COVID-19 Pandemic by Advancing TD-0903 to Treat Hospitalized Patients with Acute Lung Injury PR Newswire +5.11%
Mar-25-20 11:30AM	Theravance Bio (TBPH) Up 2.1% Since Last Earnings Report: Can It Continue? Zacks -5.40%
Mar-23-20 06:32PM	Stocks To Watch: Theravance Biopharma Sees Relative Strength Rating Jump To 94 Investor's Business Daily
Mar-20-20 08:02PM	Seth Klarman Sees Bargains as the Market Heads Further Into Chaos GuruFocus.com
Mar-02-20 07:00AM	Theravance Biopharma Announces Closing of Private Placement of $400 Million Non-Recourse Notes PR Newswire
Feb-27-20 02:49PM	Analysts Have Lowered Expectations For Theravance Biopharma, Inc. After Its Latest Results Simply Wall St.
Feb-25-20 02:53PM	Theravance (TBPH) Q4 Earnings Miss, Revenues Beat Estimates Zacks
02:06AM	Edited Transcript of TBPH earnings conference call or presentation 24-Feb-20 10:00pm GMT Thomson Reuters StreetEvents
Feb-24-20 06:15PM	Theravance Biopharma (TBPH) Reports Q4 Loss, Tops Revenue Estimates Zacks -8.77%
Feb-18-20 07:00AM	Theravance Biopharma Announces Presentations at Upcoming Investor Conferences PR Newswire
Feb-17-20 12:30PM	Analysts Estimate Theravance Biopharma (TBPH) to Report a Decline in Earnings: What to Look Out for Zacks
Feb-11-20 11:05PM	Theravance Biopharma Announces Pricing of Public Offering of Ordinary Shares PR Newswire -8.80%
02:21PM	How Does Investing In Theravance Biopharma, Inc. (NASDAQ:TBPH) Impact The Volatility Of Your Portfolio? Simply Wall St.
Feb-05-20 10:27AM	Theravance Pipeline Strong, Dependence on Yupelri a Concern Zacks
Jan-19-20 09:13AM	3 Strong Buy Biotech Stocks That Can Inject a Healthy Dose of Upside TipRanks
Jan-07-20 04:48PM	Theravance Biopharma Announces Presentation at the 38th Annual J.P. Morgan Healthcare Conference PR Newswire
Dec-24-19 09:16AM	AstraZeneca's Triple-Combo COPD Inhaler Gets China's Nod Zacks
Dec-23-19 08:15AM	Theravance Biopharma and Pfizer Inc. Enter Global License Agreement for Skin-Targeted, Locally-Acting Pan-Janus Kinase (JAK) Inhibitor Program PR Newswire
Dec-22-19 11:10AM	Hedge Funds Have Never Been Less Bullish On Theravance Biopharma Inc (TBPH) Insider Monkey
Dec-10-19 12:22PM	Seth Klarman Pares Paratek Pharmaceuticals Stake GuruFocus.com
Dec-05-19 11:31AM	Theravance Bio (TBPH) Up 25.6% Since Last Earnings Report: Can It Continue? Zacks
Dec-03-19 07:50AM	Theravance Biopharma Announces Dosing of First Patient in Phase 2 Allergen Challenge Study of TD-8236, an Investigational, Lung-Selective, Inhaled Pan-Janus Kinase (JAK) Inhibitor for Inflammatory Lung Diseases PR Newswire
Nov-26-19 04:15PM	Theravance Biopharma to Present at Two Upcoming Investor Conferences PR Newswire
Nov-09-19 10:43AM	Edited Transcript of TBPH earnings conference call or presentation 5-Nov-19 10:00pm GMT Thomson Reuters StreetEvents
Nov-06-19 04:30PM	Theravance Biopharma to Present at the 2019 Credit Suisse Healthcare Conference PR Newswire
11:19AM	Theravance (TBPH) Q3 Loss In Line, Revenues Lag Estimates Zacks
Nov-05-19 06:35PM	Theravance Biopharma (TBPH) Reports Q3 Loss, Misses Revenue Estimates Zacks
04:05PM	Theravance Biopharma, Inc. Reports Third Quarter 2019 Financial Results and Provides Business Update PR Newswire
11:24AM	What's in Store for Cumberland Pharma (CPIX) in Q3 Earnings? Zacks
Oct-29-19 04:15PM	Theravance Biopharma to Report Third Quarter 2019 Financial Results on November 5 PR Newswire
10:32AM	Theravance Biopharma (TBPH) May Report Negative Earnings: Know the Trend Ahead of Q3 Release Zacks
Oct-28-19 05:49PM	Here is What Hedge Funds Think About Theravance Biopharma Inc (TBPH) Insider Monkey
Oct-21-19 04:00PM	Theravance Biopharma and Mylan to Present New Data on YUPELRI® (revefenacin) at the 2019 CHEST Annual Meeting PR Newswire
Oct-07-19 10:25AM	Theravance Pipeline Strong, Dependence on Yupelri a Concern Zacks
Oct-02-19 01:34PM	Have Insiders Been Selling Theravance Biopharma, Inc. (NASDAQ:TBPH) Shares? Simply Wall St.
07:05AM	AstraZeneca's Triple-Combo COPD Inhaler Gets CRL From FDA Zacks
Sep-25-19 04:05PM	Theravance Biopharma to Present at the 2019 Cantor Global Healthcare Conference PR Newswire
Sep-23-19 01:16PM	Seth Klarman Further Increases Translate Bio Stake GuruFocus.com
Sep-10-19 01:58PM	Baupost's Seth Klarman Dives Further Into Translate Bio GuruFocus.com +8.88%
11:46AM	Theravance Announces Positive Early Data on JAK Inhibitor Zacks
Sep-09-19 07:05AM	Theravance Biopharma Reports Positive Results from Phase 1 Clinical Trial of TD-8236, an Investigational, Lung-Selective, Inhaled Pan-Janus Kinase (JAK) Inhibitor for Inflammatory Lung Diseases PR Newswire
Aug-28-19 04:30PM	Theravance Biopharma to Present at Two Upcoming Investor Conferences PR Newswire
Aug-12-19 10:47AM	Spectrum Pharma's (SPPI) Loss Narrows in Q2, Stock Rises Zacks
Aug-11-19 08:32AM	How Theravance Biopharma, Inc. (NASDAQ:TBPH) Can Impact Your Portfolio Volatility Simply Wall St.
Aug-09-19 08:24AM	Achillion (ACHN) Reports Wider Y/Y Loss in Q2, Revenues Nil Zacks
08:06AM	Esperion (ESPR) Q2 Loss Wider Than Expected, Revenues Beat Zacks
Aug-07-19 11:20AM	Jazz Pharma (JAZZ) Q2 Earnings and Sales Beat Estimates Zacks
Aug-05-19 09:18AM	Corcept's (CORT) Earnings & Revenues Miss Estimates in Q2 Zacks
Aug-02-19 05:44PM	Edited Transcript of TBPH earnings conference call or presentation 31-Jul-19 12:00pm GMT Thomson Reuters StreetEvents
Aug-01-19 03:37PM	Theravance (TBPH) Q2 Loss Narrower, Revenues Beat Estimates Zacks
Jul-31-19 03:27PM	Theravance Biopharma, Inc. (TBPH) Q2 2019 Earnings Call Transcript Motley Fool
08:35AM	Theravance Biopharma (TBPH) Reports Q2 Loss, Tops Revenue Estimates Zacks
07:05AM	Theravance Biopharma, Inc. Reports Second Quarter 2019 Financial Results and Provides Business Update PR Newswire

Theravance Biopharma, Inc., a diversified biopharmaceutical company, discovers, develops, and commercializes organ-selective medicines. The company offers YUPELRI, a once-daily, nebulized long-acting muscarinic antagonist used for the treatment of chronic obstructive pulmonary disease. Its product portfolio also include TD-1473, a gut-selective pan-janus kinase (JAK) inhibitor that is in Phase IIb/III clinical trials for the treatment of rheumatoid arthritis, myelofibrosis, and ulcerative colitis, as well as for a range of inflammatory intestinal diseases, including ulcerative colitis and Crohn's disease. In addition, the company's product portfolio also comprise Ampreloxetine, an investigational norepinephrine reuptake inhibitor that has completed Phase III study for neurogenic orthostatic hypotension; TD-8236, an investigational, inhaled lung-selective pan-JAK inhibitor, which is Phase II clinical study for treatment of a range of inflammatory diseases; and TD-5202, an investigational, orally administered, gut-selective, irreversible JAK3 inhibitor that is in Phase I clinical study for treatment of inflammatory intestinal diseases. Further, it offers TRELEGY ELLIPTA for the treatment of COPD; Velusetrag, an oral and investigational medicine for gastrointestinal motility disorders; and Selective 5-HT4 Agonist for treatment of gastrointestinal motility disorders. It has a licensing and collaboration agreements with Pfizer Inc., Mylan Ireland Limited, Janssen Biotech, Inc., Alfasigma S.p.A, Trek Therapeutics, PBC, and Takeda Pharmaceutical Company Limited. The company was incorporated in 2013 and is based in George Town, the Cayman Islands.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
GRAHAM RICHARD A	SVP, Development	Dec 14	Sale	19.47	7,500	146,058	123,749	Dec 16 06:09 PM
WORBOYS PHILIP D	SVP, Research & Transl Science	Dec 03	Sale	18.00	4,246	76,428	319,395	Dec 07 06:42 PM
HAUMANN BRETT K	Chief Medical Officer	Aug 21	Sale	18.29	25,000	457,240	282,810	Aug 24 06:21 PM
WORBOYS PHILIP D	SVP, Research & Transl Science	Aug 20	Sale	18.00	17,103	307,854	333,252	Aug 24 06:38 PM

open in yahoo | open in reuters | open in google

Upgrade your FINVIZ experience